DVA · 10-Q · 2026Q2

DAVITA INC.

Filed 2026-08-04 · Healthcare · View original filing on EDGAR

Ranked Events

• Share Repurchase ActivityImportance 89 · Surprise 82
  DaVita repurchased 5.243 million shares for $751.3 million during the first six months of 2026, including $382.8 million of Berkshire repurchases and $368.5 million of open-market repurchases. Total repurchases…
• Net Income and EPS PerformanceImportance 69 · Surprise 64
  Net income attributable to DaVita increased 27.8% year over year to $462.9 million for the first six months of 2026 from $362.3 million. Second-quarter attributable net income increased 33.1% to $265.4 million from…
• Operating Cash Flow TrendsImportance 69 · Surprise 64
  Six-month operating cash flow increased 60.8% to $810.9 million from $504.2 million in the prior-year period. The improvement included a $264.3 million reduction in accounts-receivable cash use, with accounts…
• Elara Caring Minority AcquisitionImportance 65 · Surprise 60
  DaVita closed its acquisition of a noncontrolling minority interest in Elara Caring on July 20, 2026 after signing the definitive agreement on February 2, 2026. The company paid $200 million in cash at closing, subject…
• Acquisitions and DivestituresImportance 65 · Surprise 82
  Cash paid for acquisitions increased to $38.5 million in the first six months of 2026 from $10.6 million in the comparable 2025 period, a 263.7% year-over-year increase. Goodwill additions from acquisitions totaled…
• Interest Rate EnvironmentImportance 64 · Surprise 42
  DaVita entered into a June 8, 2026 Ninth Amendment that added $500 million to Term Loan B-2, using proceeds to repay part of its revolving-line balance; the transaction generated $2.035 million of debt extinguishment…
• Reimbursement and Payer MixImportance 64 · Surprise 56
  Medicare and Medicare Advantage generated $3.42 billion of six-month dialysis patient service revenue, up from $3.27 billion, while Medicaid and Managed Medicaid increased to $439.8 million from $424.2 million.…
• Debt Financing and RepaymentsImportance 64 · Surprise 42
  During the six months ended June 30, 2026, DaVita incurred a $500 million incremental Term Loan B-2 tranche and drew $65 million on its revolving credit facility, while making approximately $36 million of scheduled…
• Integrated Kidney Care GrowthImportance 60 · Surprise 40
  As of June 30, 2026, DaVita IKC provided integrated care and disease-management services to approximately 64,900 patients in risk-based integrated care arrangements and another 5,700 patients in other integrated care…
• Geographic Market CommentaryImportance 59 · Surprise 48
  DaVita’s international dialysis business operated 595 outpatient dialysis centers across 14 countries outside the United States as of June 30, 2026. International revenue increased 20.9% year over year during the first…
• Revenue Performance and MixImportance 59 · Surprise 48
  Six-month consolidated revenue increased to $6.97 billion from $6.60 billion, with U.S. dialysis revenue rising to $5.92 billion from $5.71 billion and Other—Ancillary services revenue increasing to $1.05 billion from…
• Interest Rate and Refinancing ExposureImportance 52 · Surprise 42
  On July 7, 2026, DaVita entered into forward interest rate cap agreements with an aggregate notional amount of $750 million. The agreements cap exposure to SOFR variable-rate changes on specified portions of the…
• Regulatory Approval MilestonesImportance 51 · Surprise 50
  In June 2026, the Centers for Medicare & Medicaid Services issued a proposed rule addressing the Medicare End Stage Renal Disease Prospective Payment System for calendar year 2027. CMS estimates that the proposal would…
• Operating Expense TrendsImportance 49 · Surprise 32
  U.S. dialysis patient-care costs increased 3.4% year over year to $3.974 billion for the first six months of 2026, and patient-care cost per treatment increased 3.2% to $278.74. The increase was primarily caused by…
• Operating Income and MarginsImportance 49 · Surprise 32
  Consolidated operating income increased 8.6% year over year to $1.061 billion for the six months ended June 30, 2026, while total segment operating margin increased 5.2% to $1.107 billion. U.S. dialysis operating…
• Revenue Recognition and Contract AssetsImportance 46 · Surprise 56
  DaVita recognized $98.5 million of integrated kidney care revenue for performance obligations satisfied in previous years during the six months ended June 30, 2026, up from $95.9 million in the prior-year period.…
• Regulatory RiskImportance 44 · Surprise 60
  DaVita continues to face government investigations in the United States involving physician joint ventures, medical-director agreements, insurance communications, American Kidney Fund donations, and physician…
• Liquidity and Cash PositionImportance 43 · Surprise 6
  DaVita had $1.435 billion of available capacity and $65 million drawn under its $1.5 billion revolving credit facility as of June 30, 2026. No letters of credit were outstanding under the revolving facility, while…
• Treatment Volume TrendsImportance 43 · Surprise 32
  DaVita’s U.S. dialysis treatment volume increased in the second quarter of 2026, with 7.23 million treatments versus 7.03 million in the first quarter and average treatments per day rising 1.1% to 92,649.…
• Value-Based Care ContractsImportance 43 · Surprise 32
  DaVita’s integrated kidney care (IKC) risk-based arrangements require estimates of member alignment, third-party medical claims expense, quality outcomes, and risk-adjustment scores. Measurement limitations delayed…

Revenue by Product (in thousands)